XBIT
XBiotech Inc
$
2.970
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.000
Open
2.910
VWAP
2.95
Vol
21.18K
Mkt Cap
90.55M
Low
2.9046
Amount
62.43K
EV/EBITDA(TTM)
--
Total Shares
30.46M
EV
-65.96M
EV/OCF(TTM)
--
P/S(TTM)
--
XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products, including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.
Show More
Get winning stock picks in minutes
Get winning stock picks in minutes
Valuation Metrics
The current forward P/E ratio for XBiotech Inc (XBIT.O) is 0.00, compared to its 5-year average forward P/E of 32.47. For a more detailed relative valuation and DCF analysis to assess XBiotech Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
32.47
Current PE
0.00
Overvalued PE
88.99
Undervalued PE
-24.06
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
5.18
Current PS
0.00
Overvalued PS
13.16
Undervalued PS
-2.79
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+24.85%
-13.55M
Operating Profit
FY2025Q1
YoY :
+8.82%
-10.88M
Net Income after Tax
FY2025Q1
YoY :
+9.09%
-0.36
EPS - Diluted
FY2025Q1
YoY :
-8.62%
-6.81M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
XBIT News & Events
Events Timeline
2024-12-23 (ET)
2024-12-23
08:06:21
XBiotech pauses rheumatology program
Sign Up For More Events
Sign Up For More Events
News
7.0
02-04PRnewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
7.0
01-14NewsfilterWolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws
7.0
01-14GlobenewswireWolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws
Sign Up For More News
People Also Watch
FAQ
What is XBiotech Inc (XBIT) stock price today?
The current price of XBIT is 2.97 USD — it has increased 0.68 % in the last trading day.
What is XBiotech Inc (XBIT)'s business?
What is the price predicton of XBIT Stock?
What is XBiotech Inc (XBIT)'s revenue for the last quarter?
What is XBiotech Inc (XBIT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for XBiotech Inc (XBIT)'s fundamentals?
How many employees does XBiotech Inc (XBIT). have?